Semaglutide vs Retatrutide: Single vs Triple Agonist Compared
Compare semaglutide (GLP-1) vs retatrutide (triple agonist GLP-1/GIP/glucagon). Effectiveness, research status, and what the Phase 2 data shows.
| Dimension | semaglutide | retatrutide | Notes |
|---|---|---|---|
| Weight Loss Efficacy | 15-17% | 24-26% | Retatrutide Phase 2 data showed up to 24.2% weight loss at 48 weeks. Still awaiting Phase 3 results. |
| Mechanism | GLP-1 only | GLP-1 + GIP + Glucagon | Retatrutide is a triple agonist — the glucagon receptor adds thermogenic fat burning. |
| FDA Status | Approved | Phase 3 trials | Semaglutide is FDA-approved. Retatrutide is still in clinical trials (Phase 3 ongoing). |
| Side Effects | Well-documented | Limited data | Semaglutide has years of post-market safety data. Retatrutide safety profile still being established. |
| Availability | Widely available | Research only | Semaglutide available by prescription. Retatrutide only through clinical trials or research suppliers. |
| Cost | $150-1,350/mo | $200-400/mo (research) | Semaglutide ranges from compounded to brand. Retatrutide only available from research peptide vendors. |
Learn more about each peptide
Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has demonstrated significant weight loss effects in clinical trials. It is sold under the brand names Ozempic (diabetes) and Wegovy (weight management).
Retatrutide
Retatrutide is a triple hormone receptor agonist (GIP/GLP-1/glucagon) currently in Phase 3 clinical trials. Early data shows up to 24% body weight loss, potentially making it the most effective weight loss peptide ever studied.
More comparisons
Weekly peptide research updates
New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.
Reviewed by Fat Man in the Arena · Updated March 2026
Medical Disclaimer: This comparison is for informational purposes only. Individual responses vary. Always consult a qualified healthcare provider before starting any peptide protocol.